Biological Eâ??s novel Covid-19 vaccine of SARS-CoV-2 for protection against Covid-19 disease. : A prospective open label randomised phase-I seamlessly followed by phase-IIstudy to assess the safety, reactogenicity and immunogenicity of Biological Eâ??snovel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 forprotection against Covid-19 disease when administered intramuscularly in a twodose schedule (0, 28D) to healthy volunteers. - None

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

WHO International Clinical Trials Registry Platform - (2021) vom: 24. Nov. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Phase: Phase 1/Phase 2
Recruitment Status: Closed to Recruitment of Participants
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 10-11-2020, Last updated: 2022-11-24

ICTRP ID:

CTRI/2020/11/029032
BECT062/Covid-19-phase-I&II/CTP-01Ver: 1.1 dated:07.10.20

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG006503152